Adicet Bio Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$76.4M
Lead Investor(s):N/A

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Adicet Bio's estimated annual revenue is currently $14.1M per year.
  • Adicet Bio's estimated revenue per employee is $201,000
  • Adicet Bio's total funding is $76.4M.

Employee Data

  • Adicet Bio has 70 Employees.
  • Adicet Bio grew their employee count by 11% last year.
  • Adicet Bio currently has 7 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Missing a competitor? Contribute!?

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Adicet Bio News

04/30/2019 - Adicet Bio Appoints Anil Singhal Chief Executive Officer

MENLO PARK, Calif., April 30, 2019 /PRNewswire/ -- Adicet Bio, Inc., a biopharmaceutical company focused on the development of ...

05/01/2019 - OncoResponse's Anil Singhal Named Adicet Bio President ...

Anil Singhal has been appointed president and CEO of Adicet Bio. He succeeds Donald Santel, who had been interim CEO since founder and ...

08/08/2019 - Biolife Solutions Inc (BLFS) Q2 2019 Earnings Call Transcript

Some notable new automated thaw product customers included Adicet Bio, Beam Therapeutics, Bluebird Bio, BlueRock Therapeutics, Editas ...

Adicet Bio Executive Hires

2017-01-06Anne AltmeyerChief Business OfficerArticle
2017-06-29Jesse McGreivyChief Medical OfficerArticle
2017-07-03Jesse McGreivyChief Medical OfficerArticle
2018-03-07Donald Santelinterim CEOArticle
2018-05-01Elizabeth ReadCTOArticle
2018-06-28Stewart AbbotChief Scientific OfficerArticle